<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041648</url>
  </required_header>
  <id_info>
    <org_study_id>PBI L606_2.0</org_study_id>
    <nct_id>NCT04041648</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dose of L606 for Inhalation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmosa Biopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmosa Biopharm Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the Pharmacokinetics, Safety and&#xD;
      Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose&#xD;
      study design in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      L606 (Liposomal Treprostinil) Inhalation Solution and dedicated inhalation system is&#xD;
      developed by Pharmosa Biopharm Inc. intended to improve the inconvenience, as one of the&#xD;
      greatest impediments to patient satisfaction to current inhaled treprostinil therapy.&#xD;
      Pharmosa's liposomal technology offers sustained release of treprostinil which enable bid&#xD;
      treatment instead of conventional qid treatment offered by current inhaled treprostinil&#xD;
      therapy for treatment of patients with PAH (WHO Group 1).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Actual">May 12, 2020</completion_date>
  <primary_completion_date type="Actual">September 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of treatment-emergent adverse events for L606 and placebo, including abnormal laboratory events</measure>
    <time_frame>From Pre-dose to Day 10</time_frame>
    <description>Frequency, severity and seriousness of adverse events (AE) including physical examination, incident of laboratory abnormalities, 12-lead ECG parameter and vital sign assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-2hr</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>area under curve from time zero to 2 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-4hr</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>AUC from time zero to 4 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-8hr</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>area under curve from time zero to 8 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-12hr</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>area under curve from time zero to 12 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24hr</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>area under curve from time zero to 24 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tlast</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>AUC from time zero to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-âˆž</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>area under curve from time zero to infinite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>time to Maximum Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>time to half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>apparent total plasma clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>From pre-dose to 24 hours post dose</time_frame>
    <description>apparent volume of distribution during terminal phase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L606 Liposomal inhalation solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal inhalation solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L606 (Liposomal Treprostinil) Inhalation Solution 51ug</intervention_name>
    <description>Single ascending dose</description>
    <arm_group_label>L606 Liposomal inhalation solution</arm_group_label>
    <other_name>Drug: L606 (Liposomal Treprostinil) Inhalation Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>L606 Inhalation System</intervention_name>
    <description>Single ascending dose</description>
    <arm_group_label>L606 Liposomal inhalation solution</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Device: L606 Inhalation Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Solution</intervention_name>
    <description>Single ascending dose</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, of any race, 18 to 50 years of age, inclusive, at Screening.&#xD;
&#xD;
          2. Body mass index between 18.5 and 32.0 kg/m2, inclusive, at Screening.&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory&#xD;
             evaluations (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is&#xD;
             not acceptable) at Screening or Check in as assessed by the Investigator (or&#xD;
             designee).&#xD;
&#xD;
          4. Ability of the subject to generate spirometry according to minimum ATS/ERS guidance&#xD;
             criteria.&#xD;
&#xD;
          5. Females will not be pregnant or lactating, and females of childbearing potential and&#xD;
             males will agree to use contraception as detailed in Section 6.6.&#xD;
&#xD;
          6. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
          7. Agree to abstain from consuming alcohol from 72 hours prior to Check-in.&#xD;
&#xD;
          8. Agree to refrain from strenuous exercise from 7 days prior to Check-in.&#xD;
&#xD;
          9. Agree to abstain from consuming foods and beverages containing poppy seeds,&#xD;
             grapefruit, or Seville oranges from 7 days prior to Check-in.&#xD;
&#xD;
         10. Agree to abstain from consuming caffeine-containing foods and beverages from 48 hours&#xD;
             prior to Check-in.&#xD;
&#xD;
         11. Agree to abstain from consuming carbonated drinks (including sparkling water and soda)&#xD;
             from 48 hours prior to Check-in and until end of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically relevant abnormalities identified during Screening, physical examination,&#xD;
             12 lead ECG, or laboratory examinations.&#xD;
&#xD;
          2. Clinically significant history of hepatic, renal, hematological, pulmonary,&#xD;
             cardiovascular, gastrointestinal, neurological, respiratory, endocrine, genitourinary,&#xD;
             and/or musculoskeletal disease, glaucoma, psychiatric disorder, or any other chronic&#xD;
             disease, whether controlled by medication or not.&#xD;
&#xD;
          3. History of anaphylaxis, significant hypersensitivity, intolerance, or allergy to any&#xD;
             drug compound, food, or other substance, unless deemed not clinically significant by&#xD;
             the Investigator (or designee).&#xD;
&#xD;
          4. History of postural hypotension, unexplained syncope, or hypertension.&#xD;
&#xD;
          5. History of asthma, chronic obstructive pulmonary disease (COPD), or reactive airways&#xD;
             conditions or findings consistent with asthma or COPD on spirometry testing.&#xD;
&#xD;
          6. Blood pressure &lt;90 mmHg systolic or &lt;50 mmHg diastolic after supine for 5 minutes at&#xD;
             Screening or Check in upon repeat testing.&#xD;
&#xD;
          7. Blood pressure &gt;150 mmHg systolic or &gt;90 mmHg diastolic after supine for 5 minutes at&#xD;
             Screening or Check in upon repeat testing.&#xD;
&#xD;
          8. Pulse rate &gt;100 bpm after supine for 5 minutes at Screening or Check-in upon repeat&#xD;
             testing.&#xD;
&#xD;
          9. Have a pre-existing condition that could interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of drugs. Cholecystectomy is permitted if done at least 10&#xD;
             days before enrollment.&#xD;
&#xD;
         10. Use tobacco- or nicotine-containing products within 6 months prior to Check-in, or&#xD;
             have a history of &gt;1 pack cigarettes daily use over multiple years of smoking.&#xD;
&#xD;
         11. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.&#xD;
&#xD;
         12. Have a history of alcohol abuse or a history of or current impairment of organ&#xD;
             function reasonably related to alcohol abuse.&#xD;
&#xD;
         13. Have a history of or current evidence of abuse of licit or illicit drugs or a positive&#xD;
             urine screen for drugs of abuse.&#xD;
&#xD;
         14. Alcohol consumption of &gt;21 units per week. One unit of alcohol equals 12 oz (360 mL)&#xD;
             beer, 1.5 oz (45 mL) liquor, or 5 oz (150 mL) wine.&#xD;
&#xD;
         15. Positive urine drug screen (including alcohol and cotinine) at Screening and/or&#xD;
             Check-in.&#xD;
&#xD;
         16. Positive hepatitis panel and/or positive human immunodeficiency virus test at&#xD;
             Screening.&#xD;
&#xD;
         17. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) within 30 days prior to Check-in.&#xD;
&#xD;
         18. Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's Wort, within 30 days prior&#xD;
             to Check-in, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
         19. Use or intend to use any prescription medications/products within 14 days prior to&#xD;
             Check-in with the exception of hormone replacement therapy, oral, implantable,&#xD;
             transdermal, injectable, or intrauterine contraceptives, unless deemed acceptable by&#xD;
             the Investigator (or designee).&#xD;
&#xD;
         20. Use or intend to use slow-release medications/products considered to still be active&#xD;
             within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or&#xD;
             designee).&#xD;
&#xD;
         21. Use or intend to use any nonprescription medications/products or herbal supplements&#xD;
             within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or&#xD;
             designee). Use of nonsteroidal anti inflammatory drugs or aspirin is prohibited within&#xD;
             14 days prior to Check-in.&#xD;
&#xD;
         22. Receipt of blood products within 2 months prior to Check-in.&#xD;
&#xD;
         23. Donation of blood, plasma, and platelets, or the loss of a significant volume of blood&#xD;
             (&gt;450 mL) within 6 weeks prior to Screening.&#xD;
&#xD;
         24. Poor peripheral venous access.&#xD;
&#xD;
         25. Have a history of bleeding problems or abnormal bleeding tendencies.&#xD;
&#xD;
         26. Platelet or coagulation factor levels below the lower limit of normal, unless&#xD;
             considered not clinically significant by the Investigator.&#xD;
&#xD;
         27. Have previously completed or withdrawn from this study or any other study&#xD;
             investigating treprostinil, and have previously received the investigational product.&#xD;
&#xD;
         28. History of any recent infection within 2 weeks of Check-in.&#xD;
&#xD;
         29. In the opinion of the Investigator (or designee), should not participate in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L Hunt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmosa Biopharm Inc.PPD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

